Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer

Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
Condition:   Metastatic Pancreatic Cancer
Interventions:   Drug: Cemiplimab;   Drug: Plerixafor
Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Genzyme, a Sanofi Company;   American Association for Cancer Research;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 11, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments